Measuring outcomes of treatment with antiepileptic drugs in clinical trials (Q37750042)

22 August 2017

1 reference

title

Measuring outcomes of treatment with antiepileptic drugs in clinical trials (English)

1 reference

22 August 2017

Josemir W Sander

2

0 references

Frank G. Gilliam

series ordinal

4

object named as

Frank Gilliam

1 reference

22 August 2017

1

Elinor Ben-Menachem

1 reference

22 August 2017

Michael Privitera

3

1 reference

22 August 2017

publication date

13 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

18

1 reference

22 August 2017

issue

1-2

1 reference

22 August 2017

page(s)

24-30

1 reference

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

New antiepileptic drugs in practice--how do they perform in the real world?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Cross-country measures for monitoring epilepsy care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Comparative retention rates and long-term tolerability of new antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Clinical development of antiepileptic drugs in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Patient awareness of seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Epilepsy: accuracy of patient seizure counts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Optimizing health outcomes in active epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Seizure reduction and quality of life improvements in people with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Effect of age and comedication on levetiracetam pharmacokinetics and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Importance of competing risks in the analysis of anti-epileptic drug failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

A prospective analysis of the outcome of levetiracetam in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Patient adherence to treatment: three decades of research. A comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Dose Frequency and Dose Interval Compliance with Multiple Antiepileptic Medications During a Controlled Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Medication compliance and persistence: terminology and definitions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Epilepsy management issues and techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Value of therapeutic drug monitoring in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEBEH.2010.04.001

10.1016/J.YEBEH.2010.04.001

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference